WallStSmart

Accuray Incorporated (ARAY)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 8020% more annual revenue ($35.48B vs $436.97M). MDT leads profitability with a 13.0% profit margin vs -8.2%. MDT appears more attractively valued with a PEG of 1.50. MDT earns a higher WallStSmart Score of 56/100 (C).

ARAY

Hold

44

out of 100

Grade: D

Growth: 4.7Profit: 2.5Value: 4.0Quality: 3.5
Piotroski: 5/9Altman Z: -0.03

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ARAY.

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARAY2 strengths · Avg: 9.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
16.8%8/10

16.8% revenue growth

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

ARAY4 concerns · Avg: 2.5/10
Market CapQuality
$45.86M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.7%3/10

Operating margin of 3.7%

PEG RatioValuation
29.492/10

Expensive relative to growth rate

Return on EquityProfitability
-70.3%2/10

ROE of -70.3% — below average capital efficiency

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ARAY

The strongest argument for ARAY centers on Price/Book, Revenue Growth. Revenue growth of 16.8% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : ARAY

The primary concerns for ARAY are Market Cap, Operating Margin, PEG Ratio. Debt-to-equity of 3.83 is elevated, increasing financial risk.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

ARAY profiles as a growth stock while MDT is a value play — different risk/reward profiles.

ARAY carries more volatility with a beta of 1.20 — expect wider price swings.

ARAY is growing revenue faster at 16.8% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 44/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Accuray Incorporated

HEALTHCARE · MEDICAL DEVICES · USA

Accuray Incorporated designs, develops and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa and the rest of the Asia Pacific region. The company is headquartered in Sunnyvale, California.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?